COVID-19 is new and scientists understand little about how it behaves and spreads. The cost of creating a Coronavirus vaccine to protect people against the new coronavirus will run into billions of dollars and could take many months. Here are some of the reasons why.
- Time to get a COVID-19 vaccine to market is likely to be at least 18 months.
- Potential treatments require testing and funding.
- International organizations are helping to fund research.
Its complex to make vaccines
Technology is enabling new methods of exploring vaccine candidates for trial, but there are already a few tried and tested ways to make them.
In all of them, scientists try to stimulate the body’s immune system to combat invasive pathogens. That’s commonly done by creating something so similar to the pathogen that the body begins to create antibodies to fight off the real thing.
The most common way of doing this is to make what’s called attenuated vaccines – those that are made of weaker strains of the actual pathogen. Reared on animal cells outside of human bodies, they are then extracted and injected in a single tiny dose.
Vaccines for measles and tuberculosis are created in this way.
Inactivated vaccines, on the other hand, are derived from identifying the active proteins in a virus that enables them to invade human cells. That’s done by taking dead samples of the pathogen and studying their genetic make-up so that scientists can replicate them en masse. When injected into a human, the body gets to work again constructing the necessary antibodies.
Often such vaccines require multiple doses over time, including those to protect against such diseases as rabies and polio.
Then there are nucleotide-based vaccines, which seek to replicate the genetic material – DNA and RNA – of a virus. This method stimulates the body’s own creation of this viral material in order for it to produce the necessary antibodies.
The good news
Once a candidate vaccine passes through those hoops, the challenge is to produce it in the volume necessary to end a pandemic.
A number of organizations are helping to fund the process. Among them is Norway-based CEPI, the Coalition for Epidemic Preparedness Innovations.
It was first launched at the World Economic Forum’s Annual Meeting in Davos in 2017, with the intention of bringing together public, private, philanthropic and civil organizations to develop vaccines against epidemics.
Backed by the Bill & Melinda Gates Foundation, among other donors, in 2020 CEPI announced a new partnership to develop a vaccine for COVID-19.
It has issued an urgent call for $2 billion of new funding, to expand the number of vaccine candidates at the outset to increase the chances of success, and to fund the clinical trials.
“Our ambition is to have at least three vaccine candidates, which could be submitted to regulatory authorities for licensure for general use/use in outbreaks.”
CEPI has already provided funding to several organizations and institutions working on vaccines, including:
- Inovio Pharmaceuticals: Its DNA-based vaccine has begun pre-clinical trials, meaning the company is ready to test its candidate on humans.
- GlaxoSmithKline: Developing a “molecular clamp” vaccine, which would contain the protein that enables COVID-19 to enter human cells. This method was worked up by the University of Queensland in Australia.
- Moderna: The US company has already begun testing an RNA-based treatment.
It remains to be seen how long it will take until there is a workable vaccine against COVID-19. For the time being, the best way to ensure you reduce your risk of infection is to follow the World Health Organization’s advice on handwashing and social distancing.